MX2019008911A - Metodos, matrices y usos de estos. - Google Patents
Metodos, matrices y usos de estos.Info
- Publication number
- MX2019008911A MX2019008911A MX2019008911A MX2019008911A MX2019008911A MX 2019008911 A MX2019008911 A MX 2019008911A MX 2019008911 A MX2019008911 A MX 2019008911A MX 2019008911 A MX2019008911 A MX 2019008911A MX 2019008911 A MX2019008911 A MX 2019008911A
- Authority
- MX
- Mexico
- Prior art keywords
- pancreatic cancer
- methods
- determining
- test sample
- matrices
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Data Mining & Analysis (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Databases & Information Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1701572.8A GB201701572D0 (en) | 2017-01-31 | 2017-01-31 | Methods, arrays and uses thereof |
| PCT/EP2018/052423 WO2018141804A1 (en) | 2017-01-31 | 2018-01-31 | Methods, arrays and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019008911A true MX2019008911A (es) | 2019-09-26 |
Family
ID=58462729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019008911A MX2019008911A (es) | 2017-01-31 | 2018-01-31 | Metodos, matrices y usos de estos. |
Country Status (13)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008231575A1 (en) * | 2007-03-27 | 2008-10-02 | Immunovia Ab | Protein signature/markers for the detection of adenocarcinoma |
| CA3142634A1 (en) | 2019-07-03 | 2021-01-07 | Crystal Bioscience Inc. | Anti-b7-h3 antibody and methods of use thereof |
| KR102289278B1 (ko) * | 2019-07-09 | 2021-08-13 | 주식회사 베르티스 | 췌장암 진단용 바이오마커 패널 및 그 용도 |
| US20230055143A1 (en) * | 2019-12-20 | 2023-02-23 | Medimmune, Llc | Compositions and Methods of Treating Cancer with Chimeric Antigen Receptors Targeting Glypican 3 |
| GB202010970D0 (en) | 2020-07-16 | 2020-09-02 | Immunovia Ab | Methods, arrays and uses thereof |
| CA3214598A1 (en) * | 2021-03-26 | 2022-09-29 | BioNTech SE | Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer |
| CN113336851B (zh) * | 2021-06-30 | 2021-12-24 | 徐州医科大学 | 新型全人源抗人b7h3抗体、包含所述抗体的组合物及其应用 |
| WO2026028902A1 (ja) * | 2024-08-01 | 2026-02-05 | 学校法人慈恵大学 | 診断薬、膵癌診断キット、検出方法、マーカー、抗膵癌剤、及び膵癌治療用組成物 |
| CN120177800B (zh) * | 2025-05-23 | 2025-10-10 | 四川大学 | 血液生物标志物cfp在制备急性胰腺炎诊断试剂的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US8632983B2 (en) * | 2005-04-15 | 2014-01-21 | Van Andel Research Institute | Biomarkers for pancreatic cancer and diagnostic methods |
| AU2008231575A1 (en) | 2007-03-27 | 2008-10-02 | Immunovia Ab | Protein signature/markers for the detection of adenocarcinoma |
| CN103476428B (zh) * | 2010-09-09 | 2016-10-26 | 北京同为时代生物技术有限公司 | 用于诊断上皮源性癌症的血液标志物及其单克隆抗体 |
| GB201103726D0 (en) | 2011-03-04 | 2011-04-20 | Immunovia Ab | Method, array and use thereof |
| GB201206323D0 (en) * | 2012-04-10 | 2012-05-23 | Immunovia Ab | Methods and arrays for use in the same |
| GB201319878D0 (en) * | 2013-11-11 | 2013-12-25 | Immunovia Ab | Method, Array and use thereof |
| GB201516801D0 (en) * | 2015-09-22 | 2015-11-04 | Immunovia Ab | Method, array and use thereof |
-
2017
- 2017-01-31 GB GBGB1701572.8A patent/GB201701572D0/en not_active Ceased
-
2018
- 2018-01-31 RU RU2019123695A patent/RU2019123695A/ru not_active Application Discontinuation
- 2018-01-31 AU AU2018214180A patent/AU2018214180A1/en not_active Abandoned
- 2018-01-31 MX MX2019008911A patent/MX2019008911A/es unknown
- 2018-01-31 JP JP2019541330A patent/JP2020507760A/ja active Pending
- 2018-01-31 WO PCT/EP2018/052423 patent/WO2018141804A1/en not_active Ceased
- 2018-01-31 CN CN201880009309.3A patent/CN110325860A/zh active Pending
- 2018-01-31 BR BR112019015633-0A patent/BR112019015633A2/pt not_active Application Discontinuation
- 2018-01-31 US US16/479,064 patent/US20190382849A1/en not_active Abandoned
- 2018-01-31 EP EP18703545.6A patent/EP3577464A1/en not_active Withdrawn
- 2018-01-31 KR KR1020197022175A patent/KR20190109422A/ko not_active Ceased
- 2018-01-31 CA CA3051968A patent/CA3051968A1/en not_active Abandoned
-
2019
- 2019-07-24 IL IL268244A patent/IL268244A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190109422A (ko) | 2019-09-25 |
| JP2020507760A (ja) | 2020-03-12 |
| GB201701572D0 (en) | 2017-03-15 |
| AU2018214180A1 (en) | 2019-08-08 |
| EP3577464A1 (en) | 2019-12-11 |
| IL268244A (en) | 2019-09-26 |
| US20190382849A1 (en) | 2019-12-19 |
| RU2019123695A (ru) | 2021-03-02 |
| CA3051968A1 (en) | 2018-08-09 |
| WO2018141804A1 (en) | 2018-08-09 |
| BR112019015633A2 (pt) | 2020-03-17 |
| CN110325860A (zh) | 2019-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018013621A (es) | Metodo, matriz y uso de estos. | |
| MX363201B (es) | Procedimiento, matriz y uso para determinar la presencia de cancer pancreatico. | |
| MX2016006125A (es) | Procedimiento, matriz y uso de los mismos. | |
| MX2017001302A (es) | Biomarcadores para predecir la respuesta del dlbcl al tratamiento con un inhibidor de la btk. | |
| WO2017050939A3 (en) | Method and array for diagnosing pancreatic cancer in an individual | |
| BR112017007965A8 (pt) | Método implantado por computador para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; aparelho para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; meio de armazenamento não transitório; programa de computador; kits para medir níveis de expressão de três ou mais genes-alvo da via de sinalização celular de tgf-b em uma amostra de um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; e uso do kit | |
| CL2019003286A1 (es) | Ensayos de diagnóstico para detectar, cuantificar y/o rastrear microbios y otros analitos. | |
| AR095363A1 (es) | Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1 | |
| MX2017008421A (es) | Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga. | |
| MX373248B (es) | Prediccion de riesgo de evento cardiovascular y usos del mismo. | |
| MX355020B (es) | Biomarcadores de cancer de pulmon y usos de los mismos. | |
| CL2017001972A1 (es) | Biomarcadores para cáncer pancreático | |
| MX2017003790A (es) | Detección de secuencias diana por percepción de nanoporos de sondas sintéticas. | |
| MX390772B (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
| MX2016016742A (es) | Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv). | |
| BR112016019836A2 (pt) | método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito | |
| MX2016001719A (es) | Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular. | |
| BR112015023120A2 (pt) | método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado | |
| BR112022011676A2 (pt) | Kit para detectar um analito de interesse em uma pluralidade de amostras líquidas biológicas, método para detectá-lo e /ou quantificá-lo e cartucho para realizar tal método | |
| BR112018015965A2 (pt) | método para determinação de helicobacter pylori | |
| BR112018009463A2 (pt) | ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia | |
| BR112016013976A2 (pt) | método para determinar se um indivíduo é afetado por um câncer, método para discriminar entre câncer colorretal e pancreático dentre indivíduos que resultam ser positivos para o método, método para determinar o estágio de um câncer colorretal em um indivíduo afetado e uso de um kit de rt-pcr quantitativo para performar o método | |
| BR112018011224A2 (pt) | processo de avaliação do risco de complicações nos pacientes que apresentam uma síndrome da resposta inflamatória sistêmica (sirs) | |
| BR112016017926A2 (pt) | ensaio para detectar periostina humana | |
| BR112016029562A2 (pt) | métodos para tratar, diagnosticar e prognosticar uma malignidade hematológica |